Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: When do they begin to be effective?

Schizophrenia Research

Volumn 148, Issue 1-3, 2013, Pages 163-167

  Mossaheb, Nilufar ^a   Schäfer, Miriam R ^a,b   Schlögelhofer, Monika ^a   Klier, Claudia M ^a   Cotton, Susan M ^b   McGorry, Patrick D ^b   Amminger, G Paul ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

High risk; Omega 3 fatty acids; Prodrome; Psychosis; UHR

Indexed keywords

OMEGA 3 FATTY ACID; PLACEBO;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

HIGH RISK; OMEGA-3 FATTY ACIDS; PRODROME; PSYCHOSIS; UHR;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; TIME FACTORS; YOUNG ADULT;

EID: 84881027641     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.05.027     Document Type: Article

References (47)

1. Addington J., Cadenhead K.S., Cannon T.D., Cornblatt B., McGlashan T.H., Perkins D.O., Seidman L.J., Tsuang M., Walker E.F., Woods S.W., Heinssen R. North-American prodrome longitudinal study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr. Bull. 2007, 33:665-672.
2. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry 2003, 60(12):1228-1235.
3. Agid O., Seeman P., Kapur S. The "delayed onset" of antipsychotic action-an idea whose time has come and gone. J. Psychiatry Neurosci. 2006, 31(2):93-100.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DV. 4th ed.
5. Amminger G.P., McGorry P.D. Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders. Neuropsychopharmacology 2012, 37(1):309-310.
6. Amminger G.P., Schäfer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67(2):146-154.
7. Amminger G.P., Schäfer M.R., Klier C.M., Slavik J.M., Holzer I., Holub M., Goldstone S., Whitford T.J., McGorry P.D., Berk M. Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Mol. Psychiatry 2011, 17(12):1150-1152. (Dec).
8. Andreasen N.C., Liu D., Ziebell S., Vora A., Ho B.C. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am. J. Psychiatry 2013, 170(6):609-615. (Jun 1).
9. Ascher-Svanum H., Nyhuis A.W., Faries D.E., Kinon B.J., Baker R.W., Shekhar A. Clinical, functional and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr. Bull. 2008, 34(6):1163-1171.
10. Berger G.E., Proffitt T.M., McConchie M., Yuen H., Wood S.J., Amminger G.P., Brewer W., McGorry P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J. Clin. Psychiatry 2007, 68(12):1867-1875.
11. Calder P.C. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2003, 38(4):343-352.
12. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., Rostaing P., Triller A., Salem N., Ashe K.H., Frautschy S.A., Cole G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43(5):633-645.
13. Correll C.U., Malhotra A.K., Kaushik S., McMeniman M., Kane J.M. Early prediction of antipsychotic response in schizophrenia. Am. J. Psychiatry 2003, 160(11):2063-2065.
14. El-Ansary A.K., Al-Daihan S.K., El-Gezeery A.R. On the protective effect of omega-3 against propionic acid-induced neurotoxicity in rat pups. Lipids Health Dis. 2011, 10:142. (19).
15. Emsley R., Myburgh C., Oosthuizen P., van Rensburg S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 2002, 159(9):1596-1598.
16. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 2001, 158(12):2071-2074.
17. Gama C.S., Canever L., Panizzutti B., Gubert C., Stertz L., Massuda R., Pedrini M., de Lucena D.F., Luca R.D., Fraga D.B., Heylmann A.S., cbe Deroza P.F., Zugno A.I. Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: A study in adolescent rats with ketamine-induced model of schizophrenia. Schizophr. Res. 2012, 141(2-3):162-167. (Nov).
18. Gueorgieva R., Krystal J.H. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch. Gen. Psychiatry 2004, 61:310-317.
19. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
20. Kim H.Y., Akbar M., Kim K.Y. Inhibition of neuronal apoptosis by polyunsaturated fatty acids. J. Mol. Neurosci. 2001, 16(2-3):223-227. (discussion 279-284).
21. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Zhou W., Kapur S., Kane J.M. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-590.
22. Lehman A.F. Developing an outcomes-oriented approach for the treatment of schizophrenia. J. Clin. Psychiatry 1999, 60(Suppl. 19):30-35.
23. Leucht S., Busch R., Hamann J., Kissling W., Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry 2005, 57(12):1543-1549.
24. McGlashan T.H., Zipursky R.B., Perkins D., Addington J., Miller T., Woods S.W., Hawkins K.A., Hoffman R.E., Preda A., Epstein I., Addington D., Lindborg S., Trzaskoma Q., Tohen M., Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 2006, 163(5):790-799.
25. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., Germano D., Bravin J., McDonald T., Blair A., Adlard S., Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002, 59(10):921-928.
26. McNamara R.K., Sullivan J., Richtand N.M., Jandacek R., Rider T., Tso P., Campbell N., Lipton J. Omega-3 fatty acid deficiency augments amphetamine-induced behavioural sensitization in adult DBA/2J mice: relationship with ventral striatum dopamine concentrations. Synapse 2008, 62:725-735.
27. Moghaddam B. A mechanistic approach to preventing schizophrenia in at-risk individuals. Neuron 2013, 78(1):1-3. (Apr 10).
28. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
29. Morrison A.P., French P., Walford L., Lewis S.W., Kilcommons A., Green J., Parker S., Bentall R.P. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 2004, 185:291-297.
30. Morrison A.P., French P., Stewart S.L., Birchwood M., Fowler D., Gumley A.I., Jones P.B., Bentall R.P., Lewis S.W., Murray G.K., Patterson P., Brunet K., Conroy J., Parker S., Reilly T., Byrne R., Davies L.M., Dunn G. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 2012, 344:e2233. (Apr 5).
31. Mossaheb N., Schloegelhofer M., Schaefer M.R., Fusar-Poli P., Smesny S., McGorry P., Berger G., Amminger G.P. Polyunsaturated fatty acids in emerging psychosis. Curr. Pharm. Des. 2012, 18(4):576-591.
32. Mozaffarian D., Rimm E.B. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006, 296(15):1885-1899.
33. Review Erratum. JAMA Feb 14 2007, 297(6):590.
34. Nordentoft M., Thorup A., Petersen L., Ohlenschlaeger J., Melau M., Christensen T.O., Krarup G., Jørgensen P., Jeppesen P. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr. Res. 2006, 83(1):29-40.
35. O'Gorman C., Kapur S., Kolluri S., Kane J. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies. Hum. Psychopharmacol. Clin. Exp. 2011, 26:282-290.
36. Peet M., Brind J., Ramchand C.N., Shah S., Vankar G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 2001, 49(3):243-251.
37. 2 receptor synergism. Nature 1991, 353:164-167.
38. Posternak M.A., Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J. Clin. Psychiatry 2005, 66:148-158.
39. Preti A., Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr. Res. 2010, 123(1):30-36. (+#).
40. Riecher-Rössler A., Gschwandtner U., Aston J., Borgwardt S., Drewe M., Fuhr P., Pflüger M., Radü W., Schindler Ch., Stieglitz R.D. The Basel early-detection of psychosis (FEPSY) study - design and preliminary results. Acta Psychiatr. Scand. 2007, 115:114-125.
41. Rothman K.J. No adjustments are needed for multiple comparisons. Epidemiology 1990, 1:43-46.
42. Smesny S., Milleit B., Hipler U.C., Milleit C., Schäfer M.R., Klier C.M., Holub M., Holzer I., Berger G.E., Otto M., Nenadic I., Berk M., McGorry P.D., Sauer H., Amminger G.P. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Mol. Psychiatry 2013, (Epub ahead of print). 10.1038/mp.2013.7.
43. Stauffer V.L., Case M., Kinon B.J., Conley R., Ascher-Svanum H., Kollack-Walker S., Kane J., McEvoy J., Lieberman J. Early Response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res. 2011, 187:42-48.
44. 1A receptors in fish oil-mediated increased BDNF expression in the rat hippocampus and cortex: a possible antidepressant mechanism. Neuropsychopharmacology 2012, 62:184-191.
45. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., McFarlane C.A., Hallgren M., McGorry P.D. Psychosis prediction: 12-month follow-up of a high-risk ("prodromal") group. Schizophr. Res. 2003, 60(1):21-32.
46. Yung A.R., Yuen H.P., Berger G., Francey S., Hung T.C., Nelson B., Phillips L., McGorry P. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?. Schizophr. Bull. 2007, 33(3):673-681.
47. Yung A.R., Phillips L.J., Nelson B., Francey S.M., Yuen H.P., Simmons M.B., Ross M.L., Kelly D., Baker K., Amminger G.P., Berger G., Thompson A.D., Thampi A., McGorry P.D. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J. Clin. Psychiatry 2011, 72(4):430-440.